PTEN and neoplasm: This approach could support early detection of PTEN-deficient or PTEN-restored tumors, a more accurate prognosis by linking EV-derived PTEN levels to tumor stage or immune activity, and therapeutic monitoring, where dynamic changes in EV-PTEN could indicate treatment response or resistance.